← Retour au Screener

Sector: Santé
Open in Terminal → DNLILive chart · Key metrics · News · Smart money

Denali Therapeutics

DNLI Mid Cap

Healthcare · Biotechnology

Mis à jour: Jun 18, 2026, 22:21 UTC

20,34 €
-0.77% aujourd'hui
52W: 10,98 € – 21,51 €
52W Low: 10,98 € Position: 88.9% 52W High: 21,51 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
3,2 Md €
Capitalisation boursière
Croissance du CA
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-49.59%
Rentabilité des capitaux propres
Beta
1.01
Sensibilité au marché
Positions vendeuses
9.97%
% du flottant vendu à découvert
Volume moyen
1,862,373
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
15 analysts
Avg. Price Target
29,61 €
+45.57% upside
Target Range
17,45 € – 36,65 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 507 Exchange: NMS

Denali Therapeutics en bref

Denali Therapeutics (DNLI) is currently trading at 20,34 € with a market capitalization of 3,2 Md €. The 52-week range spans from 10,98 € to 21,51 €; the current price is 5.4% below the yearly high.

💰 Dividende

Denali Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

15 analystes évaluent Denali Therapeutics (DNLI) au consensus : Achat Fort. L'objectif de cours moyen est de 29,61 €, soit un potentiel de +45.57% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 17,45 € à 36,65 €.

Denali Therapeutics : la thèse d'investissement en détail

Denali Therapeutics (DNLI) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 45.57% upside from current levels — analyst sentiment is firmly constructive.

À surveiller

  • The analyst consensus price target implies 45.57% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Strong Buy
  • Bilan solide avec faible endettement (D/E 4.32)
Points faibles
  • Free cash flow négatif

Aperçu technique

MM 50 jours
17,38 €
+17.02% vs. cours
MM 200 jours
16,00 €
+27.17% vs. cours
Sous le plus haut 52s
−5.4%
21,51 €
Au-dessus du plus bas 52s
+85.3%
10,98 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Risque de marché (Bêta)
1.01 · Proche du marché
Évolue plus que le marché global
Positions vendeuses
9.97% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
4.32 · Faible
Dette totale / capitaux propres

The data points to market-like volatility, elevated short interest (9.97%).

Trading Data

50-Day MA: 17,38 €
200-Day MA: 16,00 €
Volume: 2,178,487
Avg. Volume: 1,862,373
Short Ratio: 7.54
P/B Ratio: 3.99x
Debt/Equity: 4.32x
Free Cash Flow: -166 096 744 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Denali Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut